Several viral-based shRNA library methods have been described, and have become valuable tools for conducting RNAi screens (reviewed in [@R1]--[@R3]). Microarray synthesis of shRNAs has been used to generate diverse libraries of shRNAs or microRNA-designed shRNAs, which are then cloned, sequence-verified, and arrayed into 96-well plate format [@R2], [@R4], [@R5]. To simplify screening, these barcoded shRNA constructs can be used as pools, and the resulting hits identified by recovering and hybridizing the barcodes to a microarray [@R6]--[@R9]. These strategies have been widely implemented with many successes[@R6]--[@R9], and such libraries are commercially available (e.g. Open Biosystems, Sigma, TRC libraries).

A central shortcoming of existing lentiviral libraries is their low diversity (typically 3--5 shRNAs/gene), which results in high rates of both false negatives and false positives. False negatives occur because currently available algorithms (e.g., [@R10]) cannot ensure the presence of effective hairpins specific to a target gene. For the same reason, false positives become problematic because more than one effective shRNA/target must be present to rule out off-target effects. The use of high diversity libraries would allow for identification of multiple potent shRNAs/target (a critical control in RNAi experiments[@R11]), while increasing the sensitivity of RNAi screens.

Existing shRNA libraries have typically utilized extensive cloning, sequencing, and often addition of a vector-specific "barcode" sequence to each shRNA before it is included in the library, a time-consuming and costly process. Recent improvements in microarray-based oligonucleotide synthesis allow the production of long oligos (\>100 bp) with an error rate of less than 1/250 bp (data not shown). These oligos should allow a direct clone-and-use strategy that would allow easy adoption of changes in RNAi technology, vector choice, or assay design.

Accordingly, we generated pooled shRNA libraries that (1) have highly expanded per-gene coverage (∼30 shRNAs/gene), (2) are easy to construct and inexpensive to screen, (3) can be used directly as shRNA pools, and (4) can be readily quantitated by microarray and deep sequencing following a screen ([Fig. 1](#F1){ref-type="fig"}). To this end, we designed a pilot library encoding 22,000 shRNAs to target ∼600 genes, including nearly all known human CD antigens (CD antigen shRNA library). To maintain the high fidelity and diversity of the input oligo library, we carefully optimized conditions for PCR amplification, cloning, and propagation of the shRNA library (see methods, and [Supplementary Note 1](#SD1){ref-type="supplementary-material"}).

To determine the mutation frequency in the shRNA library, we sequenced 122 random shRNA inserts. 64% of the clones were correct ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The errors in the remainder generally consisted of 1--2 nucleotide mutations or deletions. While it is likely that many of the imperfect shRNA sequences retain effectiveness in gene knockdown[@R12]--[@R14], these mutants can be identified by deep sequencing and removed from downstream analysis. We repeatedly created CD antigen shRNA libraries, with 60--80% correct shRNA sequences ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

PCR amplification can lead to a reduction in complexity of an shRNA mixture during multiple cycling steps. To assess the library complexity, we deep sequenced PCR-amplified shRNAs and identified ∼95% of the expected shRNAs ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), with error rates consistent with our previous single clone measurements ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). It is also possible to monitor these libraries using microarrays and improved half-hairpin probes[@R7]--[@R9]. Either approach would allow the direct identification of shRNAs, and eliminate the need to independently barcode each vector.

Since we obtained a reasonably low error rate and nearly complete shRNA coverage, it seemed likely that the libraries could be used directly in RNAi experiments. As a functional test, we infected human Raji B cells with the CD antigen shRNA library, and sorted infected cells (expressing mCherry as a marker for infection) that also displayed reduced expression of CD45. The initial comparison of cells seven days after infection with either the control virus or the shRNA library showed no notable difference during the first sort. However, after two rounds of sorting with cells cultured for seven days between sorts, we observed a substantial enrichment for mCherry+ CD45^low^ cells as compared to cells infected with vector alone (35.9% vs. 9.62%) ([Fig. 2](#F2){ref-type="fig"}). To identify active anti-*CD45* shRNAs, we PCR-amplified and cloned the lentiviral shRNA inserts from genomic DNA isolated from the CD45^low^ sorted cells. Of 83 sequenced shRNA clones, 39 targeted *CD45* (46%). Given that the starting population of the library contained 0.15% *CD45*-targeting shRNAs (33 out of 22,000), this represents an enrichment of \> 300 fold accomplished in a two step sort procedure.

Although other shRNAs were detected in the enriched fraction, we only detected multiple distinct shRNAs for *CD45*, highlighting the power of the expanded library to unambiguously detect 'hits' in a single screen. In this initial experiment we recovered 6 unique *CD45*-targeting shRNAs in the sorted CD45^low^ fraction from the total of 33 *CD45*-targeting shRNAs present in the library. These active shRNAs differed markedly in abundance within the sorted fraction ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). In general, the shRNAs that were recovered in larger numbers were also more potent when they were individually re-tested for *CD45* knockdown ([Supplementary Table 3, Fig. 2](#SD1){ref-type="supplementary-material"}). Therefore, the expanded library yielded a diverse population of target-specific shRNAs in a single experiment, and allowed us to obtain information about the potency of each individual shRNA from the relative number of each shRNA recovered.

Recent developments in deep sequencing technology make it possible to simultaneously measure the presence of \> 80 million distinct sequences at a typical read length of ∼50--70 nucleotides, which is ideally suited to monitor the shRNA sequences in the library described here. A digital readout allows the clear resolution of even very similar shRNA species, which is important for the determination of efficacy of individual shRNAs in high complexity libraries. In addition, mutant shRNAs can be directly detected and discarded from further analysis, which is not possible using microarray hybridization assays. This should be particularly useful when measuring the loss of shRNAs that cause cell death or slow growth (dropout screens), where the presence of inactive mutant shRNAs would complicate the interpretation of results. Finally, the large capacity of deep sequencing allows the detection of subtle changes in abundance within genome-scale populations of shRNAs.

To evaluate the capacity of deep sequencing to accurately measure sequence abundance over a broad range of concentrations, we performed a dilution series with a known set of 32 oligonucleotides with unique 28-mer sequence tags. We could detect a highly linear distribution of oligonucleotide counts over an ∼ 1 × 10^6^ concentration range ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Sequences which were read less than ∼10 times were less reliably measured, but can be accurately measured by simply increasing the sequencing coverage.

The large dynamic range and linearity of this counting approach suggested that deep sequencing could be used to measure the change in abundance of shRNA species at early time points in our test screen. To this end, we used deep sequencing coupled with binned flow cytometry based-sorting to search for shRNAs targeting *CD45*. Human Raji B cells were infected with the CD antigen shRNA library and grown for 1 week, after which they were sorted into 6 fractions representing different levels of CD45 expression ([Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Genomic DNA was prepared from the sorted fractions, shRNAs were amplified by PCR, and the abundance of each shRNA in the various fractions was assessed by deep sequencing. Remarkably, even though a population of CD45^low^ cells was undetectable by flow cytometry at this early time point ([Fig. 2](#F2){ref-type="fig"}), we could readily measure substantial enrichment of multiple active anti-*CD45* shRNAs in the CD45^low^ fractions ([Fig. 3b](#F3){ref-type="fig"}). This included all anti-*CD45* shRNAs identified in the previous experiment, which involved two rounds of highly selective sorting performed over several weeks. Importantly, although the shRNAs were present at unequal levels at the beginning of the experiment, normalization of their abundance in CD45^low^ fractions to a fraction with high CD45 expression could clearly identify enrichment for multiple active anti-*CD45* shRNAs.

The ability to identify multiple active shRNAs specific for each gene is one of the most critical improvements of our approach over existing methodologies, and is a direct consequence of including 33 shRNAs per gene in the library. Taking into account the full range of shRNAs for each gene, a rigorous statistical test can be performed to differentiate true hits from genes that by chance have one or two off-target shRNAs. This allows the assignment of a P value to every screened gene (rather than to single shRNAs). Using this method, we could readily resolve anti-*CD45* shRNAs from the rest of the library ([Fig. 3c](#F3){ref-type="fig"}); (*P* \< 2 × 10^−7^, see [Supplementary Note 2](#SD1){ref-type="supplementary-material"}). In contrast, the large majority of shRNAs were not significantly enriched in any fraction. This result was not unique to a particular CD antigen or cell type, as we obtained similar results when sorting for different CD antigens (LAIR1/CD305 in U937 cells or CD3 in Jurkat cells). *LAIR1* and *CD3*-specific shRNAs could be clearly resolved from the rest of the library (*P* = 2.6 × 10^−5^ and *P* = 1.1 × 10^−7^, respectively)([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}).

To further test the ability of our method to enrich for active target-specific shRNAs, we individually cloned and analyzed the potency of 33 anti-*CD45* shRNAs predicted by an algorithm[@R15] ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Only about 50% of these had minimal activity (\> 25% knockdown), and only 6 had \> 60% knockdown. In general, while we could see substantial enrichment for active shRNAs after a single sort, there was little enrichment for shRNAs with low activity. Nonetheless, the correlation between activity and enrichment was not perfect, possibly because of off-target effects of some shRNAs.

Interestingly, the highly active shRNAs were not restricted to those predicted to be most active by the algorithm; indeed, the most active species were often quite low on the list. We observed similar results when testing shRNAs directed against *LAIR1* ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). This analysis illustrates a key advantage of our expanded-coverage library: without including 30 shRNAs per gene it would have been impossible to predict enough functional shRNAs to corroborate hits. As data accumulates on which hairpins are most active, shRNA prediction algorithms can be improved and library sizes reduced.

In summary, our approach provides an efficient method for rapidly creating and screening shRNA libraries, which addresses both false negative and false positive problems that commonly plague RNAi screens. With only ∼20--30% of predicted hairpins giving \> 50% knockdown ([Supplementary Fig. 5--6](#SD1){ref-type="supplementary-material"}), low complexity libraries will often not have enough shRNAs to corroborate genuine hits in a screen. We show here that high-coverage shRNA libraries can identify many shRNAs targeting a single gene, which increases confidence in hits obtained in RNAi screens. The increased complexity of these libraries can be deconvoluted through deep sequencing. We further show that this method allows detection of active shRNA hits in a model screen without extensive selection, sorting, and cell proliferation, which will greatly facilitate efforts to identify essential genes whose absence may slow growth or cause cell death. Finally, the direct clone-and-use method provides the flexibility to easily remake libraries to immediately incorporate continual advances in RNAi technology, such as various microRNA contexts for expression and improved algorithms for shRNA prediction.

Methods {#S1}
=======

Amplification, digestion, cloning, and preparation of shRNA library {#S2}
-------------------------------------------------------------------

To design shRNAs against CD antigens, we used the shRNA prediction algorithm freely available through the Hannon lab website: <http://katahdin.cshl.org:9331/homepage/portal/scripts/main2.pl>[@R15]. The output shRNA sequences were then modified to have a 9-bp loop (TTCAAGAGA) and common primer binding sites compatible with cloning into the lentiviral vector pSicoR-mCherry which drives stable expression of the hairpin via a mouse U6 promoter[@R16]: 5\': CGCCTGCGAGTCTGGTATg, 3': GGAATTCGCCAGCTCGAG (reverse complement). A 22,000-element, 96-bp oligonucleotide pilot library was designed using these sequences, and was provided by Agilent Technologies as a pool in a single tube (4 pmol) and dissolved in 200 µL water. Improvements to fidelity of long oligonucleotides were made by minimizing the synthetic cycle loss during coupling and deblock, and by minimizing the depurination side reaction.

We identified optimal conditions for amplification of full-length product (96 bp oligos) by using Phusion DNA polymerase (Finnzymes), varying the amount of DMSO, annealing temperature, and extension times for the PCR on a Bio-Rad iCycler. Final conditions were for 50 µl reaction: 30 µl water, 10 µl 5x Phusion GC buffer, 1 µl 10 mM dNTPs, 5 µl 5 µM primer mix, 0.5 µl template, 1 µl DMSO, 0.5 µl Hot Start Phusion polymerase (Finnzymes). Cycling parameters were 98 °C for 30 s; 15 cycles of (98 °C for 10 s and 72 °C for 30 s); 72 °C for 10 min. Primers: 5\': CGCCTGCGAGTCTGGTAT, 3': GGAATTCGCCAGCTCGAG. Note that all primers used in this study are listed in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}.

The PCR-amplified oligos were purified using a nucleotide removal kit (Qiagen) according to manufacturer's recommendations, and subjected to restriction digest in a 70 µl reaction containing 1 µg DNA, 7 µl 10x NEB buffer 4, 0.7 µl 100x BSA, 40 U of *Xho*I and *Mly*I (2 µl *Xho*I, 4 µl *Mly*I), and incubated in 37 °C waterbath for 6 H. Digested fragments were verified by electrophoresis on 20% PAGE-TBE with 0.5% TBE running buffer, and purified over a second Qiagen nucleotide removal column before cloning into pSicoR-mCherry.

To prepare the vector for cloning, pSicoRmCherry was subject to restriction digest in a 150 µl reaction containing 15 µl NEB buffer 4, 1.5 µl BSA, 5 µg pSicoR-mCherry, 50 U each of *Xho*I and *Hpa*I (NEB), and incubated overnight at 37 °C. Vector was then treated (without purification) with Antarctic Phosphatase (NEB) in a 150 µl reaction containing 16.9 µl Antarctic Phosphatase buffer and 12.5 U enzyme for 4 H at 37 °C. Vector was then purified on an 0.8% agarose gel, cut out, and subject to gel-extraction using the QIAquick gel purification it (Qiagen). Vector was then phenol-chloroform extracted, ethanol precipitated, and resuspended in 20 µl water. A second library type was cloned using primers for mir30-context shRNAs as previously described[@R4], [@R5], using the above parameters, except cloning was performed by digestion with *Xho*I and *EcoR*I.

Ligations were performed in a 20 µl reaction containing 500 ng vector, 30 ng insert, 2 µl 10X ligase buffer (NEB), 2000 U T4 DNA ligase (NEB), and were incubated at 16 °C for 16 H.

To preserve the diversity of the library, colonies were scraped from twelve 15 cm plates directly after transformation of the ligation mixture (six 100 µl transformations of max-efficiency DH5a cells (Invitrogen)). Plates contained about 50,000 colonies each. The collected cell pellet was used for maxiprep (Qiagen) directly, and enough DNA was recovered from the plates for numerous viral preps.

Isolation of CD45, LAIR1, or CD3-targeting shRNAs {#S3}
-------------------------------------------------

To select shRNAs that specifically target the human *CD45* receptor, *LAIR1/CD305*, or *CD3*, we prepared concentrated virus from the CD-antigen library and control (no insert) pSicoR-mCherry vectors as described previously[@R16]. 2 × 10^6^ human Raji B cells, U937 cells, or Jurkat cells (ATCC) were infected with virus at an MOI of 0.1 to ensure single integration sites of the viruses. After 7 days of culture, ∼ 5 × 10^7^ cells were incubated on ice for 15 min with 500 µl of PBS containing 20% normal mouse serum, 5% BSA, and 10% FCS to block non-specific interactions. Subsequently, PE-conjugated anti-CD45 (BD Biosciences), APC-conjugated anti-LAIR1 (R&D), or APC-conjugated anti-CD3ϵ (BD Biosciences) was added and allowed to interact with the cells for 30 min, followed by two washes with Hanks' BSS medium supplemented with 2% FCS. mCherry positive (as a marker for infected cells) and CD45 or LAIR-1-reduced cells (to select potential active anti-*CD45* or anti-*LAIR1* shRNAs) were sorted by using a MoFlow cell sorter (Dako Cytomation). After a week of culture the same procedure was repeated, and the cells were cultured for an additional 7 days. Note that for the binning/deep sequencing experiment, cells were infected and sorted after 7 days. For further details of binning/sorting, see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. All of the sequences for the CD antigen shRNA library as well as the effective shRNAs targeting *CD45* and *LAIR1* are included as [Supplementary Data 1--3 online](#SD1){ref-type="supplementary-material"}.

To re-test anti-*CD45* shRNAs following the 2-sort experiment, genomic DNA was isolated from the sorted cell fractions, and lentiviral shRNA integrations were amplified by PCR using the primers: 5': TGCAGGGGAAAGAATAGTAGAC, and 3': AGTTATGTAACGCGGAACTCC, cloned into the pCR2.1-TOPO vector (Invitrogen), and sequenced. Identified *CD45*-targeting shRNAs were subcloned into pSicoR-mCherry, packaged into lentivirus and individually validated for their efficiency in CD45 knock-down, essentially as described above. Analysis of cells after viral infection and surface antigen staining was performed on an LSR II flow cytometer (BD Biosciences) and the FACS data was analyzed by FlowJo software (Tree Star, Inc.). Percent knockdown is calculated by ((Geo-mean of uninfected cells minus Geo-mean of infected cells)/Geo-mean of uninfected cells)\*100.

Amplification of shRNA pools from genomic DNA {#S4}
---------------------------------------------

shRNAs were amplified from genomic DNA in a 50 µl PCR reaction consisting of 30 µl water, 10 µl 5x Phusion GC buffer (Finnzymes), 5 µl 5 µM primer mix, 1 µl 10 mM dNTPs, 1.5 µl DMSO, 750 ng genomic DNA, and 1U (0.5 µl) Phusion polymerase (Finnzymes). Cycling parameters were 98 °C for 30 s, then 25 cycles of (98 °C for 30 s, 56 °C for 15 s, 72 °C for 15 s), then 72 °C for 10 min. Primers for amplification of shRNAs from genomic DNA were 5\' ATAAATATCCCTTGGAGAAAAGC, 3\' GGCGGTAATACGGTTATCCA. In some cases many PCR reactions were pooled on a minelute column (Qiagen) before electrophoresis on 20% PAGE with 0.5% TBE running buffer, electroelution, and concentration on a second column.

Deep Sequencing, and Quantitation of Read Accuracy {#S5}
--------------------------------------------------

Genomic DNA was prepared as before, and shRNAs were amplified as before, except sequences compatible with annealing to the Illumina flow cell were added. Final primer sequences were: 5': AATGATACGGCGACCACCGACACTCTTTCCCTCCCTTGGAGAAAAGCCTTGTTtG and 3': CAAGCAGAAGACGGCATACGA ATGGATCCTA GTACTCGAG. Note that parts of these oligonucleotide sequences are copyrighted by Illumina, Inc. The sequencing primer used was CACTCTTTCCCTCCCTTGGAGAAAAGCCTTGTTTG. Sequencing was performed according to manufacturer's protocols (Illumina).

For assessing linearity of sequence counting over a dilution series, thirty-one 68mer oligos consisting of a unique 28 nt tag flanked by 21 nt and 19 nt common Illumina primer binding sites were individually amplified by PCR and purified from an acrylamide gel. The dsDNA products were quantified using a BioAnalyzer (Agilent Technologies), and pooled with a dilution strategy designed to give a broad range of expected sequence tag concentrations. This pool was subjected to deep sequencing, and reads were aligned with the tag library allowing up to 3 mismatches against the tag.
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![Schematic for Microarray Synthesis, Cloning, and Enrichment\
Microarrays containing 22,000 shRNAs with ∼30 shRNAs per gene are synthesized, and released from the array into a single pool. shRNAs are amplified, cloned, and packaged into lentivirus. Cells infected with the lentiviral shRNA library are sorted by FACS according to phenotype. shRNAs from different fractions are PCR amplified and quantitated either by microarray hybridization or deep sequencing.](nihms112301f1){#F1}

![Raji cells sorted for low CD45 expression are enriched for anti-*CD45* shRNAs\
Raji B cells were infected with the CD antigen shRNA library (top panels) or control virus (no insert, lower panels), allowed to grow for 7 days, and sorted by FACS for reduced expression of CD45 and expression of mCherry in two rounds (7 days between sorts). Boxes indicate the gates used to sort CD45-downregulated cells. The percentage of mCherry+ cells displaying reduced CD45 expression is indicated in the figure.](nihms112301f2){#F2}

![Binned flow-sorting coupled with deep sequencing can quantitatively resolve active shRNAs after a single sort\
(**a**) Raji B cells infected with the CD antigen shRNA library were grown for 7 days and sorted into the indicated fractions. (**b**) Genomic DNA was prepared from cells collected from the fractions in A, and the shRNAs were PCR amplified and deep sequenced. The percentage of total reads for each shRNA in each fraction for *CD45* is depicted; shRNAs are sorted in order of abundance in fraction 1. (**c**) The abundance of each shRNA in fraction 1 was normalized to its abundance in fraction 5. Only *CD45* gave a significant *P* value (\< 2 × 10^−7^).](nihms112301f3){#F3}
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